>I think that the more important point is that the FDA should prefer Cinryze because it is safer.<
In any case, I think CSL Behring made a wise decision to forego the prophylactic indication in the US. Any change to the manufacturing process or the formulation to enable either a longer half-life or sub-q administration would have necessitated spending a significant amount of money—probably more money than the indication is worth even with orphan exclusivity.
Market Data 
Markets 
AI
